33 related articles for article (PubMed ID: 35792426)
1. An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takeuchi E; Ogino H; Kondo K; Okano Y; Ichihara S; Kunishige M; Kadota N; Machida H; Hatakeyama N; Naruse K; Nokihara H; Shinohara T; Nishioka Y
Thorac Cancer; 2024 Jan; 15(3):248-257. PubMed ID: 38087769
[TBL] [Abstract][Full Text] [Related]
2. Absolute Eosinophil Count Predicts Intensive Care Unit Transfer Among Elderly COVID-19 Patients From General Isolation Wards.
Huang J; Zhang Z; Liu S; Gong C; Chen L; Ai G; Zhu X; Zhang C; Li D
Front Med (Lausanne); 2020; 7():585222. PubMed ID: 33251234
[No Abstract] [Full Text] [Related]
3. The Association Between Modified Albumin-Bilirubin (mALBI) and Survival in Advanced Non-small Cell Lung Cancer Patients Treated With Immunotherapy.
Xu X; Shi X; Zhou D; Cao D
Cureus; 2024 Mar; 16(3):e56074. PubMed ID: 38618479
[TBL] [Abstract][Full Text] [Related]
4. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.
Guo X; Chen S; Wang X; Liu X
Front Immunol; 2023; 14():1138483. PubMed ID: 37081866
[TBL] [Abstract][Full Text] [Related]
5. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
[TBL] [Abstract][Full Text] [Related]
6. Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy.
Zheng LP; Yang J; Chen XW; Li LC; Sun JG
Ther Adv Med Oncol; 2023; 15():17588359231163807. PubMed ID: 37113734
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities.
Mehra T; Dongre K; Boesing M; Frei P; Suenderhauf C; Zippelius A; Leuppi JD; Wicki A; Leuppi-Taegtmeyer AB
Cancer Med; 2023 Jun; 12(11):12253-12262. PubMed ID: 37084178
[TBL] [Abstract][Full Text] [Related]
8. Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance.
Zhou J; Chu X; Zhao J; Xie M; Wu J; Yu X; Fang Y; Li Y; Li X; Su C
Biol Proced Online; 2023 Jul; 25(1):21. PubMed ID: 37488517
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities.
Stares M; Brown LR; Abhi D; Phillips I
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672590
[TBL] [Abstract][Full Text] [Related]
10. Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.
Tsai YT; Schlom J; Donahue RN
J Exp Clin Cancer Res; 2024 Mar; 43(1):82. PubMed ID: 38493133
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors.
Krizova L; Benesova I; Zemanova P; Spacek J; Strizova Z; Humlova Z; Mikulova V; Petruzelka L; Vocka M
J Cancer Res Clin Oncol; 2024 Feb; 150(2):99. PubMed ID: 38383923
[TBL] [Abstract][Full Text] [Related]
12. Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Marinkovic M; Stojanovic-Rundic S; Stanojevic A; Ostojic M; Gavrilovic D; Jankovic R; Maksimovic N; Stroggilos R; Zoidakis J; Castellví-Bel S; Fijneman RJA; Cavic M
Front Genet; 2023; 14():1245594. PubMed ID: 37719698
[No Abstract] [Full Text] [Related]
13. Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takeuchi E; Kondo K; Okano Y; Ichihara S; Kunishige M; Kadota N; Machida H; Hatakeyama N; Naruse K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
Thorac Cancer; 2023 Oct; 14(30):3042-3050. PubMed ID: 37669914
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability.
Tostes K; Siqueira AP; Reis RM; Leal LF; Arantes LMRB
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569262
[TBL] [Abstract][Full Text] [Related]
15. Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.
Caliman E; Fancelli S; Ottanelli C; Mazzoni F; Paglialunga L; Lavacchi D; Michelet MRG; Giommoni E; Napolitano B; Scolari F; Voltolini L; Comin CE; Pillozzi S; Antonuzzo L
Cancer Treat Res Commun; 2022; 32():100603. PubMed ID: 35792426
[TBL] [Abstract][Full Text] [Related]
16. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
17. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy.
Hu WT; Zhang Q; Zhang Z; He X; Zhou M; Guo Y; Wang X
Front Immunol; 2023; 14():1112409. PubMed ID: 36949952
[TBL] [Abstract][Full Text] [Related]
18. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
